VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including... VX-148 is a developed for the treatment of autoimmune diseases.
- Mechanism
- Curator reviewed
VX-148 is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication.
- Primary indication
- Investigated for use/treatment in autoimmune diseases, psoriasis and psoriatic disorders, and viral infection.Curator reviewed
- Code names
- VX-148
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with VX-148, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account